Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting

28 Feb 2019

Leuven, Belgium, 28 February 2019 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it will present  at the 9th European Society of Retina Specialists (EURETINA) Winter Meeting, which is being held March 1-2, 2019 in Prague, Czech Republic at the Clarion Congress Hotel.

The poster “Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model” shows results of the inhibitory effect of repeated administration of THR-149, Oxurion’s novel plasma kallikrein (PKal) inhibitor, on retinal vascular leakage and inflammation in the diabetic rat STZ model, compared to vehicle-treated eyes. These positive results highlight THR-149’s potential as a treatment option for diabetic macular edema (DME). Oxurion is currently conducting a Phase 1 clinical study evaluating the safety of THR-149 in DME patients with initial data read out expected towards the end of 2019.

Patrik De Haes, M.D., CEO of Oxurion nv, commented: “We look forward to presenting the results of our preclinical research with THR-149 in the field of DME at the EURETINA Winter Meeting. The results of the study demonstrate the potential therapeutic benefits of THR-149, our plasma kallikrein inhibitor, on the key disease hallmarks of DME including retinal vascular leakage and inflammation. These results further substantiate the disease-modifying capabilities of this novel drug candidate and its potential to address the clear unmet need for improved treatment options for diabetic eye disease.

Press release attachment: